AstraZeneca's ‘Discrepancies’ in Vaccine Trial Accounts Spark Questions | WHAT REALLY HAPPENED

AstraZeneca's ‘Discrepancies’ in Vaccine Trial Accounts Spark Questions

Despite pressure to carry out further studies after two cases of serious illness, British-Swedish pharmaceutical company AstraZeneca has already resumed trials of its COVID-19 vaccine in Britain, Brazil, India, and South Africa, although the tests are still on hold in the US amid concerns from the National Institutes of Health.

As US health authorities show reluctance to allow pharmaceutical company AstraZeneca to resume clinical trials of its coronavirus vaccine, a plethora of questions remain unanswered regarding the neurological illnesses reportedly suffered by study participants after they received injections of the experimental vaccine.

Earlier in September AstraZeneca and its partner, the University of Oxford, announced two neurological illnesses registered by the volunteers in their tests.

They subsequently offered various accounts of the sick trial subjects which, instead of allaying concerns, seemed to generate more questions.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA